Evidence for Anti-VEGF Treatment of Diabetic Macular Edema
Authors:
- F. BandelloF. Bandello
- L. BerchicciLBL. Berchicci
- C. La SpinaCSC. La Spina
- M. Battaglia ParodiMPM. Battaglia Parodi
- P. IaconoPIP. Iacono
- 1 August 2012
- journal article
- review article
- Published by S. Karger AG in Ophthalmic Research
- Vol. 48 (Suppl. 1) , 16-20
Abstract
Diabetic macular edema (DME) is the most important cause of vision loss in patients with diabetes mellitus. Diabetic retinopathy has a remarkable impact on public health and on the quality of life of diabetic patients and thus requires special consideration. The first line of treatment remains the management of systemic risk factors but is often insufficient in controlling DME and currently, laser retinal photocoagulation is considered the standard of care. However, laser treatment reduces the risk of moderate visual loss by approximately 50% without guaranteeing remarkable effects on visual improvement. For these reasons, new strategies in the treatment of DME have been studied, in particular the use of anti-vascular endothelial growth factor (anti-VEGF) drugs. VEGF is a pluripotent growth factor that acts as a vasopermeability factor and an endothelial cell mitogen. For this reason, it represents an interesting candidate as a therapeutic target for the treatment of DME. The aim of this article is to review the evidence behind the use of anti-VEGF drugs in the treatment of DME.Keywords
This publication has 28 references indexed in Scilit:
- New approaches for the treatment of diabetic macular oedema: recommendations by an expert panelEye, 2012
- RANDOMIZED TRIAL EVALUATING SHORT-TERM EFFECTS OF INTRAVITREAL RANIBIZUMAB OR TRIAMCINOLONE ACETONIDE ON MACULAR EDEMA AFTER FOCAL/GRID LASER FOR DIABETIC MACULAR EDEMA IN EYES ALSO RECEIVING PANRETINAL PHOTOCOAGULATIONRetina, 2011
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2010
- Diabetic Macular Edema2010
- Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2009
- Randomized Trial of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Macular Photocoagulation in Diabetic Macular EdemaOphthalmology, 2009
- Predicted biological activity of intravitreal VEGF TrapBritish Journal of Ophthalmology, 2008
- A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular EdemaOphthalmology, 2007
- The role of growth factors in the pathogenesis of diabetic retinopathyExpert Opinion on Investigational Drugs, 2004